Radioiodine therapy in patients with Graves' disease and the effects of prior carbimazole therapy.

摘要: The use of radioiodine as the first line treatment in Graves' disease is restricted India because its limited availability and an unrealistic risk perception associated with it. Additionally, effectiveness ablation influenced by many factors. Prior medical antithyroid therapy one such important factor. Aims: To analyze efficacy low dose (5 mCi) naive patients comparison to that which it was already primed drug, carbimazole. Settings Design: A non-randomized, interventional study conducted Department Medicine Endocrinology a tertiary care institute South India. Materials Methods: had two groups; Group (36 naive, uncomplicated patients) B (34 on carbimazole prior therapy). Both groups baseline clinical, biochemical evaluation were reassessed at 3 6 months for evaluating clinical status possible documentation cure. Results: cure rate 61.1% drug group 58.8% pretreated following ( P = 0.845). Higher 999m technicium (99m Tc) uptake, male gender, BMI higher free thyroxine (fT4) level predicted failure therapy. Conclusions: Administration does not alter radioiodine. Low fixed radioactive iodine may be safe effective primary therapeutic option drugs.